Prevention of osteonecrosis of the jaw in the treatment with bone modifying agents


MUDr. Lucie Reifová

Ústav radiační onkologie, Nemocnice Na Bulovce, Praha



Bone metastases are the major cause of morbidity and sometime mortality of patients with malignant tumours. The cancer with metastases is an incurable disease, however bone metastases are well influenced by modern systemic treatment targeted to bone - bisphosphonates and denosumab - bone modifying agents (BMA). This treatment significantly improves the quality of life of patients with bone metastases and often prolongs their life. However, it is necessary to be able to handle these substances. It is very important to start treatment early, long-term treatment, cooperation with patient and prevention and management of side effects. Bisphosphonates and denosumab are also indicated in the treatment of osteoporosis, but at a much lower dose than in the treatment of bone metastases. BMA therapy related osteonecrosis of the jaw is very difficult to treat and often leads to interruption or termination of this therapy. It is extremely important to prevent this undesirable situation.


Key words

bone metastases, denosumab, bisphosphonates, osteonecrosis of the jaw



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...